Vera Therapeutics (VERA) Stock
Clinical biotech developing immune and respiratory treatments. Here's the price, business snapshot, and what's worth knowing about Vera Therapeutics in June 2026.
Vera Therapeutics Inc (VERA) is a clinical-stage biotechnology company developing novel therapies targeting immune-mediated and respiratory conditions. With a market capitalisation of around US$1.94bn, it attracts attention from investors interested in innovation-driven small caps. The company’s value largely depends on pipeline progress, clinical trial results and regulatory milestones, so share price can be volatile. For long-term investors, key considerations include the strength of the balance sheet, upcoming data readouts, partner and licensing agreements, and competitive landscape. Vera may offer upside if trials succeed, but there is significant risk if development programmes encounter delays or negative results. This summary provides general, educational information — not personalised investment advice. Investors should review company filings, seek professional advice if needed and only invest money they can afford to risk, because biotech stocks can experience wide price swings and outcomes are uncertain.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying VERA's stock, indicating strong potential for price increase.
Financial Health
VERA Therapeutics has a solid book value and generates strong cash flow, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring VERA
Oncology Repurposing: Could Autoimmune Buyouts Surge?
Gilead Sciences has agreed to acquire Ouro Medicines for up to $2.175 billion to secure its advanced T-cell engager therapies. This strategic buyout reflects a growing industry trend of repurposing oncology technologies to treat severe autoimmune diseases.
Published: 24 March 2026
Explore BasketTYK2 Inhibitors: Might Oral Drugs Rule Autoimmune?
Alumis's breakthrough trial results for its oral psoriasis drug have highlighted the massive potential of advanced autoimmune therapies. This theme focuses on the pharmaceutical companies pioneering next-generation oral treatments, particularly selective TYK2 inhibitors, which represent a new frontier in convenient and effective patient care.
Published: 7 January 2026
Explore BasketRinvoq vs Humira Results | Immunology Market Shift
AbbVie's new arthritis drug, Rinvoq, has proven superior to its predecessor, Humira, signaling a major shift in the immunology market. This theme focuses on the innovative pharmaceutical companies poised to benefit from the demand for more effective autoimmune disease treatments.
Published: 21 October 2025
Explore BasketThe Post-Pandemic Pediatric Pivot
The FDA's potential withdrawal of Pfizer's COVID vaccine for young children is reshaping the pediatric pharmaceutical landscape. This regulatory shift could create a significant market opening for other drugmakers focused on pediatric vaccines and therapies.
Published: 13 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage focus
Pipeline milestones and trial readouts are primary value drivers; successful data can boost prospects, though outcomes are uncertain and can move prices sharply.
Scientific innovation
Investment interest often centres on novel approaches and partnerships, but scientific promise does not guarantee commercial success.
Market dynamics
Competition, regulatory environment and financing needs shape the opportunity; consider diversification since biotech stocks can be volatile.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
